TUMOUR-SPECIFIC antigens expressed at the cell surface of aminoazo dye induced rat hepatomata are discrete components of the plasma membrane and can be isolated in subcellular membrane fractions following homogenization of tumour cells either by intracytoplasmic cavitation with nitrogen gas (Baldwin and Moore, 1969a) or by controlled mechanical rupture under conditions where nuclear damage is minimized (Baldwin and Glaves, 1972) . Furthermore, the membrane associated antigen on one hepatoma, D23, has been solubilized by limited papain digestion of tumour membrane fractions and subsequent fractionation has yielded an essentially homogeneous protein with an approximate molecular weight of 55,000 (Baldwin, Harris and Price, 1973) . In all of these studies, the antigenicity of subcellular fractions of tumour was assayed by their capacity to absorb antibody from tumour immune sera, prepared in syngeneic rats, this being measured by reduction of the membrane immunofluorescence staining with viable hepatoma D23 cells (Baldwin and Moore, 1969a; Baldwin and Glaves, 1972; . The antigens detected in this manner showed the same individual tumour specificity as the tumour rejection antigensdemonstrable by tumour transplantation methods (Baldwin and Barker, 1967a) and by the cytotoxicity of serum and lymph node cells for cultured hepatoma cells , the implication being that tumour rejection antigens were being isolated. It was also established that the methods could be employed to isolate membrane fractions retaining tumour * Present address: Immunology Division, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester, M20 9BX. specific antigens from a spontaneously arising rat mammary carcinoma (Baldwin and Embleton, 1970 ) and 3-methylcholanthrene induced rat sarcomata (Baldwin, Pimm and Price, to be published) and again the isolated membrane preparations expressed antigenic specificities identical to those demonstrable on intact cells by tumour rejection assays.
Comparable studies have similarly established that soluble tumour specific antigens can be isolated from carcinogen induced guinea-pig sarcomata (Oettgen et al., 1968; Holmes, Kahan and Morton, 1970; Suter et al., 1972) . Extraction of tumour with 3 mol/l KCI has also been used to solubilize tumour specific antigens associated with guinea-pig hepatomata (Meltzer et al., 1971) and rat sarcomata (Thomson .
These studies draw attention to the possible use of subcellular tumour fractions for immunotherapy. More important, however, is the contribution of immune responses to tumour cell fractions in tumour bearing hosts, since recent studies have established that circulating tumour specific antigen is detectable in the serum of rats bearing transplanted hepatomata (Baldwin, Bowen and Price, 1973) and sarcomata (Thomson, Steele and Alexander, 1973) . In the rat hepatoma system it has been shown that circulating tumour antigen can modify the effective mediation of tumour immunity by inhibiting lymphocyte cytotoxicity whilst immune complexes may also act at the level of the effector cells, inhibiting their cytotoxicity, or blocking target tumour cells from lymphocyte attack Robins, 1972, 1973b) .
The objective of the present investigation was to analyse the cellular and humoral immune responses to subcellular fractions of hepatomata in order to ascertain whether these responses will contribute to, or act antagonistically against, tumour immunity elicited against intact tumour cells and known to exist also in tumour bearing rats (Baldwin, Embleton and Robins., 1973 Tumours.-Hepatomata were originally induced by oral administration of 4-dimethylaminoazobenzene (DAB), and were carried as transplant lines in syngeneic rats of the same sex as the primary host (Baldwin and Barker, 1967a (Baldwin and Moore, 1969a) . In early tests, homogenization was carried out on cell suspensions in a sucrose buffer, pH 7*4 (Ozer and Wallach, 1967) , but in later experiments minced tumour tissue was homogenized in a medium containing NaHCO3 (1 x 10-3 mol/l) and CaCl2 (2 x 10-3 mol/]), pH 7-6. Afterrelease ofN2 gas, EDTA was added to the homogenate to give a concentration of 1 x 10-3mol/l, and nuclei were removed by centrifugation twice at 600 g for 15 min. A total extranuclear membrane (ENM) fraction was isolated from the supernatant by centrifugation at 105,000 g for 60 min. The 105,000 g supernatant was concentrated by dialysis against Aquacide (Calbiochem Ltd., London, England) to give a soluble " cell sap " fraction.
A plasma membrane fraction was also isolated from tumour cells as described by Moore (1968, 1969b) . Cells were gently stirred for 16 hours at 2°C in 0.9% w/v NaCl. They were harvested by centrifugation at 600 q for 15 min and extracted with distilled water to a point short of cell lysis. Eluted membrane material was collected from the aqueous extract by centrifugation at 80,000 g for 30 min.
The protein concentration of subcellular fractions was assayed by the method of Lowry et al. (1951 In some experiments rats were immunized with heavily irradiated (15,000 rad) tumour cells by 3-8 subcutaneous inoculations at 2-week intervals (Baldwin and Barker, 1967a Immunofluorescence test.-A membrane immunofluorescence test was employed to detect tumour specific humoral antibody in the sera of immunized rats, as previously described (Baldwin and Barker, 1967b; . A fluorescence index (FI) was calculated as the proportion of unstained cells in samples exposed to normal rat serum, minus the proportion of unstained cells in the sample exposed to test serum, divided by the former figure. An Fl of 0 30 or greater represents a statistically significant positive reaction.
Colony inhibition tests.-Colony inhibition (CI) tests were carried out to detect lymph node cell (LNC) mediated immunity and complement dependent cytotoxic antibody against hepatoma cells, as described by . Target cells were hepatoma cell lines serially propogated in vitro as monolayers in Eagle's minimum essential medium (MEM) supplemented with calf serum (10%), penicillin (200 i.u./ml) and streptomycin (100 ,ug/ml).
In addition to studying LNC and antisera separately, the blocking effect of sera from ENM immunized rats on colony inhibition mediated by LNC from rats immunized with heavily irradiated tumour grafts was examined. In these tests, target cells (1 to 2 x 103) were plated in 4 ml of medium into 5 cm plastic petri dishes and incubated for 24 hours at 37°C. The medium was removed and replaced by either normal rat serum or test serum (0.1 ml) diluted with MEM (0 4 ml). Sera were inactivated at 56°C for 30 min before use. The dishes were incubated at 37°C for 30 min and the serum was removed. LNC (5 x 106 cells in 0 5 ml MEM) from normal or immune rats were then added, followed by a further 45 min incubation. MEM containing 10% calf serum (3 5 ml) was added to the LNC in each dish and the cultures were incubated for 6 days. The hepatoma cell colonies developing were fixed in methanol, stained with 1% aqueous crystal violet and counted. Three to 4 dishes were used for each combination of LNC and serum.
The percentage CI in the presence of each serum was calculated by comparing the number of colonies formed in dishes treated with immune LNC with those in dishes treated with normal LNC. Percent abrogation of CI was calculated by comparing %CI in the presence of test serum with %CI in the presence of normal rat serum. The results were evaluated statistically by Student's t test.
RESULTS

Tumour rejection tests
Experiments in which the capacity of subcellular fractions of hepatoma D23 to produce immunoprotection in syngeneic rats against a low-dose (103 cells) challenge with hepatoma D23 are summarized in Table I . In only one of the 5 experiments with the total extranuclear membrane fraction (ENM) of hepatoma D23 was there any protective response to challenge with hepatoma D23 cells but these rats failed to reject a second challenge with 5 X 103 tumour cells. Likewise, no protection was produced with a plasma membrane fraction prepared by aqueous elution of hepatoma D23 cells, although both this fraction and the ENM preparations retain hepatoma D23 specific antigen, as assayed by their capacity to absorb antibody from syngeneic tumour immune sera (Baldwin and Moore, 1969a (Table III) . Of the 13 preparations tested, only 3 produced significant inhibition of colony formation so that the LNC mediated response to hepatoma D23 ENM was much less consistent than that elicited by intact cells D23, D30 and D31 could specifically protect the homologous target tumour cells from the cytotoxic action of sensitized lymph node cells (Table V) . The sensitized LNC used in each test were from rats immunized by repeated implantation of irradiated tumour followed by a series (2-8) of challenges with viable tumour cells. In the case of hepatomata D30 and D31 LNC were also taken from rats 14 and 21 days respectively after excision of hepatoma grafts. In the tests with hepatoma D23, pretreatment of plated tumour cells with normal serum did not abolish their susceptibility to hepatoma D23 sensitized lymph node cells and in each of the 4 tests significant inhibition of colony formationwas obtained ). In the first experiment pretreatment of plated hepatoma D23 cells with D23 ENM immune sera reduced the CI from 66.7% to 6-1 and 2* 1% respectively, this representing 90 7- 96.7% abrogation of LNC cytotoxicity. In contrast, treatment with hepatoma D30 ENM antiserum had no effect so that the colony inhibition was slightly greater (72.4%) than that observed with cells treated with normal serum. This is consistent with the known immunological specificities of the tumour antigens associated with these hepatomata and indicates that the blocking action of ENM antisera is a specific event.
D23 cells in suspension (
Pretreatment of plated tumour cells with sera from rats immunized against ENM preparations of hepatoma D30 and D31 also specifically inhibited the cytotoxicity of sensitized LNC. In tests with hepatoma D30 pretreatment of plated hepatoma cells with 3 different sera from rats immunized with ENM fractions of the Target  cells  D23  D23  D23  D23  D23  D23  D23  D23  D23  D23  D30  D30  D30  D31  D31  D31  D31  D31  D30  D30  D30  D31  D31  D31 sensitized LNC cytotoxicity, whereas sera from D30 ENM immunized rats were without effect.
Impairment of host resistance to hepatoma D23 following pretreatment of rats with hepatoma D23 membrane These experiments were designed to ascertain whether immunization against hepatoma D23 ENM, which preferentially elicits a humoral immune response, would modify the tumour rejection response elicited by irradiated hepatoma cells. (Table VI) . Rats pretreated with hepatoma D23 ENM, and subsequently immunized with irradiated hepatoma D23 grafts, were not able to reject a challenge with hepatoma D23 cells which developed into progressively growing tumours in all recipients. Likewise, immunization with D23 ENM followed by irradiated normal liver failed to induce any immunity against hepatoma D23. Control rats receiving only irradiated hepatoma D23 cells all elicited a specific resistance against hepatoma D23 (Baldwin and Barker, 1967a) . With this form of immunization there is an effective cell mediated immune response so that lymph node cells taken from rats post-excision inhibit colony formation, or cell survival as assayed by the microcytotoxicity test (Baldwin et al., 1 973b) . Cytotoxic antibodyis also demonstrable in post-excision sera, but these sera do not show positive immunofluorescence staining with viable hepatoma cells. Rats immunized by repeated implantation of 60Co y-irradiated hepatoma also specifically reject subsequent challenges with cells of the same tumour. This form of immunization again provokes a significant cellular immune reaction and in this case, tumour-specific antibody is demonstrable both by serum cytotoxicity and membrane immunofluorescence reactions (Baldwin and Barker, 1967b; .
The failure of hepatoma membrane immunization to evoke tumour rejection reactions, therefore, appears to be associated with an immune deviation favouring the formation of tumour specific antibody. This is further emphasized by the finding that serum from rats immunized with hepatoma membrane specifically blocks hepatoma cells in vitrofrom cytotoxic attack by lymph node cells from tumour immune donors. Even more important than this effect at the efferent level was the observation that prior immunization with hepatoma D23 membrane specifically impairs the capacity of rats to elicit a tumour rejection response on subsequent immunization with irradiated tumour, pointing to a regulatory effect on the lymphoid system.
These observations are pertinent in respect of current developments, suggesting that interference by circulating humoral factors, including tumour antigen, antibody and immune complexes, on cell mediated immunity is of paramount importance in the outcome of a tumour immune response (Baldwin et al., , 1973b (Baldwin et al., 1973a) . Blocking at the level of the target cells, it is postulated, is mediated by tumour specific immune complexes since these sera have been shown to contain such factors in a region of antigen excess . Moreover, the blocking effect of immune complexes has been established in model studies using complexes prepared by addition of papain solubilized hepatoma D23 antigen and post-excision sera as a source of tumour specific antibody . Direct inhibition of lymphocyte reactivity can be effected by solubilized hepatoma D23 antigen (Baldwin et al., 1973b) so that the effect observed with tumour bearer ser-um may also be induced by circulating antigen or immune complexes. When these humoral factors are analysed in relation to tumour status, it is found that following surgical removal of tumour the serum factors producing tumour cell blocking and lymphocyte inhibition are rapidly lost, and at this stage tumour specific cytotoxicity antibody becomes demonstrable . On subsequent repeated immunization, tumour immune sera continue to demonstrate complement dependent cytotoxicity and antibody is demonstrable by membrane immunofluorescence. At this stage these antisera, in the absence of complement show blocking activity, protecting hepatoma cells in vitro from sensitized lymph node cells, but do not directly inhibit lymph node cell reactivity (Baldwin et al., 1973a, b (Baldwin et al., 1973b) . Additionally, circulating tumour antigen may act to inhibit the production of sensitized lymphocytes in a manner analogous to the observed lymphocyte anergy in local nodes draining a tumour (Alexander et al., 1969) .
These studies with transplanted rat hepatomata indicate the limitations of using antigenically active subcellular tumour fractions for tumour immunization. Comparably, it has been established that immunization with membrane fractions from 3-methylcholanthrene induced sarcomata and a spontaneous mammary carcinoma (Baldwin and Embleton, 1970;  Baldwin, Pimm and Price, to be published) does not result in the development of a tumour rejection reaction. It cannot be generalized from these studies, however, that tumour fractions cannot be used to induce tumour immunity since, for example, injection of soluble extracts of guinea-pig sarcomata induced a degree of resistance comparable with that obtained with intact cells (Holmes et al., 1970; Suter et al., 1972) . The conditions governing the type of response elicited against different tumours in a variety of species have yet to be defined but one important condition is likely to be the degree of stability of the tumour antigen within the cell membrane. The present observations are also pertinent to studies now in progress attempting to utilize immunostimulants such as B.C.G. for immunotherapy. For example, with Moloney sarcomata in the rat, B.C.G. immunostimulation before, or at the time of, tumour transplantation produces an immunoprotective response, whereas when given 2 weeks after, tumour enhancement is obtained (Bansal and Sjogren, 1973) . Under the latter condition it is highly probable that in addition to the local tumour mass soluble or particulate tumour antigen will be present in the circulation and from the rat hepatoma studies reported here, the type of immune response will be different from that arising where only local tumour is present, favouring a humoral antibody response. Although this has not been analysed in depth, one consequence of B.C.G. in rats bearing established Moloney sarcomata is an increase in serum blocking factors, which is consistent with the findings from the present studies with rat hepatomata showing enhanced antibody levels. This work was supported by the Cancer Research Campaign.
